Cited by 1,730Renal cell carcinoma treatmentEar and Head TumorsCancer, Hypoxia, and Metabolism

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Mutations of the VHL tumour suppressor gene in renal carcinoma

Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D.R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N.H., Grossman, H.B., Brauch, H., Pomer, S., Brooks, J.D., Isaacs, W.B., Lerman, M.I., Zbar, B., Linehan, W.M.·1994·Nature Genetics

DOI 10.1038/ng0594-85

Open this paper in CoChat — free account

Abstract

Multiple, bilateral renal carcinomas are a frequent occurrence in von Hippel-Lindau (VHL) disease. To elucidate the aetiological role of the VHL gene in human kidney tumorigenesis, localized and advanced tumours from 110 patients with sporadic renal carcinoma were analysed for VHL mutations and loss of heterozygosity (LOH). VHL mutations were identified in 57% of clear cell renal carcinomas analysed and LOH was observed in 98% of those samples. Moreover, VHL was mutated and lost in a renal tumour from a patient with familial renal carcinoma carrying the constitutional translocation, t(3;8)(p14;q24). The identification of VHL mutations in a majority of localized and advanced sporadic renal carcinomas and in a second form of hereditary renal carcinoma indicates that the VHL gene plays a critical part in the origin of this malignancy.

Integrity signals

Registry

Crossref · 10.1038/ng0594-85

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J. R., Yao, M., Duh, F.-M. C., Orcutt, M. L., Stackhouse, T. M., Kuzmin, I., Modi, W. S., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,971
Self-citation
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (1969) · The Journal of Urology · doi:10.1016/s0022-5347(17)62331-0 · Cited by 1,303
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P. J., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,298
Hereditary cancer, oncogenes, and antioncogenes.
Knudson, A. G. (1985) · PubMed · Cited by 1,218
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.10.095 · Cited by 1,160
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Höppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,143
Diseases of the kidney
Strauss, M. B., & Welt, L. G. (1963) · Little, Brown eBooks · Cited by 823
Mutations of the RET proto-oncogene in Hirschsprung's disease
Edery, P., Lyonnet, S., Mulligan, L. M., Pelet, A., Dow, E., Abel, L., Holder, S., Nihoul‐Feketé, C., Ponder, B. A. J., & Münnich, A. (1994) · Nature · doi:10.1038/367378a0 · Cited by 746
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease
Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kääriäinen, H., et al. (1994) · Nature · doi:10.1038/367377a0 · Cited by 698
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D. G., Kwok, J. B., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-70 · Cited by 643

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 1

Glenn, G.M., Choyke, P.L., Zbar, B. & Linehan, W.M. von Hippel-Lindau disease: clinical review and molecular genetics. Problems Urol. 4, 312–330 (1990).

Sorted by citations

Items 301–400 of 1,002

Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
Carril-Ajuria, L., Santos, M., Roldán‐Romero, J. M., Rodríguez‐Antona, C., & de Velasco, G. (2019) · Cancers · doi:10.3390/cancers12010016 · Cited by 109
Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives
Joosten, S. C., Hamming, L. C., Soetekouw, P. M. M. B., Aarts, M. J. B., Veeck, J., van Engeland, M., & Tjan‐Heijnen, V. C. G. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.11.002 · Cited by 113
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel‐Lindau gene status
Rini, B. I., Jaeger, E., Weinberg, V. E., Sein, N., Chew, K., Fong, K., Simko, J., Small, E. J., & Waldman, F. M. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06376.x · Cited by 111
Quantifying cancer progression with conjunctive Bayesian networks
Gerstung, M., Baudis, M., Moch, H., & Beerenwinkel, N. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp505 · Cited by 109
Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein
Ohh, M., Takagi, Y., Aso, T., Stebbins, C. E., Pavletich, N. P., Zbar, B., Conaway, R. C., Conaway, J. W., & Kaelin, W. G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8161 · Cited by 109
Self-citation
Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma
Yu, Z., Lv, Y., Su, C., Lu, W., Zhang, R., Li, J., Guo, B., Yan, H., Liu, D., Yang, Z., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2224 · Cited by 116
Downstream Targets of VHL/HIF-α Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance
Mazumder, S., Higgins, P. J., & Samarakoon, R. (2023) · Cancers · doi:10.3390/cancers15041316 · Cited by 118
von Hippel-Lindau disease: Clinical and molecular perspectives
Clifford, S. C., & Maher, E. R. (2001) · Advances in cancer research · doi:10.1016/s0065-230x(01)82003-0 · Cited by 106
A 3D human renal cell carcinoma-on-a-chip for the study of tumor angiogenesis
Miller, C. P., Tsuchida, C., Zheng, Y., Himmelfarb, J., & Akilesh, S. (2018) · Neoplasia · doi:10.1016/j.neo.2018.02.011 · Cited by 105
Overexpression of miR‐210, a downstream target of HIF1α, causes centrosome amplification in renal carcinoma cells
Nakada, C., Tsukamoto, Y., Matsuura, K., Nguyen, T. L., Hijiya, N., Uchida, T., Sato, F., Mimata, H., Seto, M., & Moriyama, M. (2011) · The Journal of Pathology · doi:10.1002/path.2860 · Cited by 108
Selective Inhibition of Carbonic Anhydrase IX Decreases Cell Proliferation and Induces Ceramide-Mediated Apoptosis in Human Cancer Cells
Cianchi, F., Vinci, M. C., Supuran, C. T., Peruzzi, B., Giuli, P. D., Fasolis, G., Perigli, G., Pastoreková, S., Papucci, L., Pini, A., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.167270 · Cited by 105
Renal cell carcinoma for the nephrologist
Perazella, M. A., Dreicer, R., & Rosner, M. H. (2018) · Kidney International · doi:10.1016/j.kint.2018.01.023 · Cited by 106
Recommendations by the Asian Pacific society of nephrology ( APSN ) on the appropriate use of HIF‐PH inhibitors
Yap, D. Y. H., McMahon, L. P., Hao, C., Hu, N., Okada, H., Suzuki, Y., Kim, S. G., Lim, S. K., Vareesangthip, K., Hung, C., et al. (2020) · Nephrology · doi:10.1111/nep.13835 · Cited by 106
Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma
Kamiya, Y. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.25 · Cited by 105
Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis
España, J., Warren, A. Y., Chew, S. K., Adams, D. J., & Matakidou, A. (2017) · Nature Communications · doi:10.1038/s41467-017-02245-1 · Cited by 109
Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas.
Vortmeyer, A. O., Lubensky, I. A., Fogt, F., Linehan, W. M., Khettry, U., & Zhuang, Z. (1997) · Europe PMC (PubMed Central) · Cited by 104
Self-citation
Adipose-derived exosomes deliver miR-23a/b to regulate tumor growth in hepatocellular cancer by targeting the VHL/HIF axis
Liu, Y., Tan, J., Ou, S., Chen, J., & Chen, L. (2019) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-019-00692-6 · Cited by 103
Frequent Loss of Heterozygosity on Chromosomes 3p and 17p without VHL or p53 Mutations Suggests Involvement of Unidentified Tumor Suppressor Genes in Follicular Thyroid Carcinoma
Grebe, S. K. G., McIver, B., HAY, I. D., Wu, P. S.-C., Maciel, L. M. Z., Drabkin, H. A., Goellner, J. R., Grant, C. S., Jenkins, R. B., & Eberhardt, N. L. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.11.3684 · Cited by 103
Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers
Agathanggelou, A., Dallol, A., Zöchbauer‐Müller, S., Morrissey, C., Honorio, S., Hesson, L. B., Martinsson, T., Fong, K. M., Kuo, M., Yuen, P. W., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206243 · Cited by 102
Self-citation
Differential Genetic Alterations in von Hippel-Lindau Syndrome-Associated and Sporadic Pheochromocytomas
Bender, B., Gutsche, M., Gläsker, S., Müller, B., Kirste, G. R., Eng, C., & Neumann, H. P. H. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.12.7015 · Cited by 102
Renal Cell Carcinoma With Clear Cell and Papillary Features
Ross, H. M., Martignoni, G., & Argani, P. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0479-ra · Cited by 101
Loss of Von Hippel–Lindau (VHL) Tumor Suppressor Gene Function: VHL–HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC)
Kim, H., Shim, B. Y., Lee, S., Lee, J. Y., Lee, H. J., & Kim, I.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189795 · Cited by 109
The inducible elongin A elongation activation domain: structure, function and interaction with the elongin BC complex.
Aso, T., Haque, D., Barstead, R. J., Conaway, R. C., & Conaway, J. W. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00940.x · Cited by 101
The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system
Gläsker, S., Bender, B., Apel, T. W., Natt, E., Velthoven, V. V., Scheremet, R., Zentner, J., & Neumann, H. P. H. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.67.6.758 · Cited by 100
DNA copy number changes associated with characteristic LOH in islet cell carcinomas of transgenic mice
Shi, Y. P., Naik, P., Dietrich, W. F., Gray, J. W., Hanahan, D., & Pinkel, D. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199706)19:2 · Cited by 22
Direct Interaction of the β-Domain of VHL Tumor Suppressor Protein with the Regulatory Domain of Atypical PKC Isotypes
Okuda, H., Hirai, S.-I., Takaki, Y., Kamada, M., Baba, M., Sakai, N., Kishida, T., Kaneko, S., Yao, M., Ohno, S., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1347 · Cited by 99
Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease
Lenglet, M., Robriquet, F., Schwarz, K., Camps, C., Couturier, A., Hoogewijs, D., Buffet, A., Knight, S. J. L., Gad, S., Couvé, S., et al. (2018) · Blood · doi:10.1182/blood-2018-03-838235 · Cited by 103
Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location
Maranchie, J. K., Afonso, A. M., Albert, P. S., Kalyandrug, S., Phillips, J. L., Zhou, S., Peterson, J. C., Ghadimi, Β. M., Hurley, K., Riss, J., et al. (2003) · Human Mutation · doi:10.1002/humu.10302 · Cited by 98
Self-citation
Understanding the Importance of Smart Drugs in Renal Cell Carcinoma
Patard, J., Rioux-Leclercq, N. C., & Fergelot, P. (2006) · European Urology · doi:10.1016/j.eururo.2006.01.016 · Cited by 98
Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma
Patard, J.-J., Rioux-Leclercq, N. C., Masson, D., Zerrouki, S., Jouan, F., Collet, N., Dubourg, C., Lobel, B., Denis, M. G., & Fergelot, P. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605298 · Cited by 104
Cooperation and Antagonism among Cancer Genes: The Renal Cancer Paradigm
Peña‐Llopis, S., Christie, A. L., Xie, X.-J., & Brugarolas, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0360 · Cited by 101
An Analysis of Phenotypic Variation in the Familial Cancer Syndrome von Hippel–Lindau Disease: Evidence for Modifier Effects
Webster, A. R., Richards, F. M., MacRonald, F. E., Moore, A. T., & Maher, E. R. (1998) · The American Journal of Human Genetics · doi:10.1086/302037 · Cited by 98
Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
Bosma, N. A., Warkentin, M. T., Gan, C. L., Karim, S., Heng, D. Y. C., Brenner, D. R., & Lee‐Ying, R. M. (2022) · European Urology Open Science · doi:10.1016/j.euros.2021.12.007 · Cited by 100
General Transcription Factors for RNA Polymerase II1
Conaway, R., & Conaway, J. W. (1997) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)61009-0 · Cited by 99
Genetic analysis of synchronous mucinous tumors of the ovary and appendix
Chuaqui, R. F., Zhuang, Z., Emmert‐Buck, M. R., Bryant, B. R., Nogales, F. F., Tavassoli, F. A., & Merino, M. J. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90370-6 · Cited by 97
Metabolic alterations in renal cell carcinoma
Massari, F., Ciccarese, C., Santoni, M., Brunelli, M., Piva, F., Modena, A., Bimbatti, D., Fantinel, E., Santini, D., Liang Cheng, C., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.07.002 · Cited by 99
Kaposi's Sarcoma–Associated Herpesvirus Viral IFN Regulatory Factor 3 Stabilizes Hypoxia-Inducible Factor-1α to Induce Vascular Endothelial Growth Factor Expression
Shin, Y. C., Joo, C.-H., Gack, M. U., Lee, H.-R., & Jung, J. U. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2766 · Cited by 97
PREVALENCE OF MICROSCOPIC TUMORS IN NORMAL APPEARING RENAL PARENCHYMA OF PATIENTS WITH HEREDITARY PAPILLARY RENAL CANCER
Ornstein, D. K., Lubensky, I. A., Venzon, D. J., Zbar, B., Linehan, W. M., & Walther, M. M. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67893-7 · Cited by 96
Self-citation
Fine-needle aspiration of the adult kidney
Renshaw, A. A., Granter, S. R., & Cibas, E. S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970425)81:2 · Cited by 96
Renal cell carcinoma: recent progress and future directions.
Mulders, P., Figlin, R. A., deKernion, J. B., Wiltrout, R. H., Linehan, W. M., Parkinson, D., deWolf, W., & Belldegrun, A. S. (1997) · PubMed · Cited by 96
Self-citation
Molecular foundations of cancer: New targets for intervention
Karp, J. E., & Broder, S. E. (1995) · Nature Medicine · doi:10.1038/nm0495-309 · Cited by 96
Clear-cell papillary renal cell carcinoma: 24 cases of a distinct low-grade renal tumour and a comparative genomic hybridization array study of seven cases
Adam, J., Couturier, J., Molinié, V., Vieillefond, A., & Sibony, M. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.03857.x · Cited by 95
The von Hippel–Lindau tumor suppressor gene product represses oncogenic β-catenin signaling in renal carcinoma cells
Peruzzi, B., Athauda, G., & Bottaro, D. P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606850103 · Cited by 95
A Novel Ankyrin Repeat-containing Gene (Kank) Located at 9p24 Is a Growth Suppressor of Renal Cell Carcinoma
Sarkar, S., Roy, B. C., Hatano, N., Aoyagi, T., Gohji, K., & Kiyama, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204244200 · Cited by 94
Genomics and epigenomics of renal cell carcinoma
Maher, E. R. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.06.003 · Cited by 93
The adjuvant treatment of kidney cancer: a multidisciplinary outlook
Porta, C., Cosmai, L., Leibovich, B. C., Powles, T. B., Gallieni, M. A., & Bex, A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0131-x · Cited by 93
Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel—Lindau protein
Na, X., Duan, H. O., Messing, E. M., Schoen, S. R., Ryan, C. K., di Sant'Agnese, P. A., Golemis, E. A., & Wu, G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg410 · Cited by 93
Aerobic glycolysis: a novel target in kidney cancer
Shuch, B. M., Linehan, W. M., & Srinivasan, R. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.57 · Cited by 95
Self-citation
Understanding familial and non-familial renal cell cancer
Bodmer, D. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2489 · Cited by 92
Androgen receptor increases hematogenous metastasis yet decreases lymphatic metastasis of renal cell carcinoma
Huang, Q., Sun, Y., Ma, X., Gao, Y., Li, X., Niu, Y., Zhang, X., & Chang, C. (2017) · Nature Communications · doi:10.1038/s41467-017-00701-6 · Cited by 91
Sorafenib
Rini, B. I. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.4.453 · Cited by 91
Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes.
Thrash-Bingham, C., Greenberg, R. E., Howard, S., Bruzel, A., Bremer, M., Goll, A., Salazar, H., Freed, J. J., & Tartof, K. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2854 · Cited by 91
DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras
Soejima, K., Fang, W., & Rollins, B. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206510 · Cited by 91
DNA Adducts, Mutations, and Cancer 2000
Hemminki, K., Koskinen, M., Rajaniemi, H., & Zhao, C. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1431 · Cited by 91
The Nephrologist’s Tumor: Basic Biology and Management of Renal Cell Carcinoma
Hu, S. L., Chang, A., Perazella, M. A., Okusa, M. D., Jaimes, E. A., Weiss, R. H., & for the American Society of Nephrology Onco-Nephrology Forum (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121335 · Cited by 91
Obesity is associated with a higher risk of clear‐cell renal cell carcinoma than with other histologies
Lowrance, W. T., Thompson, R. H., Yee, D. S., Kaag, M. G., Donat, S. M., & Russo, P. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08706.x · Cited by 90
Pheochromocytoma in Von Hippel-Lindau Disease
Hes, F. J., Höppener, J. W. M., & Lips, C. J. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021466 · Cited by 90
Pseudohypoxic Pathways in Renal Cell Carcinoma
Bratslavsky, G., Sudarshan, S., Neckers, L., & Linehan, W. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2510 · Cited by 93
Self-citation
Diverse Effects of Mutations in Exon II of the von Hippel-Lindau (VHL) Tumor Suppressor Gene on the Interaction of pVHL with the Cytosolic Chaperonin and pVHL-Dependent Ubiquitin Ligase Activity
Hansen, W. J., Ohh, M., Moslehi, J. J., Kondo, K., Kaelin, W. G., & Welch, W. J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.6.1947-1960.2002 · Cited by 90
Regulation of urokinase plasminogen activator/plasmin- mediated invasion of melanoma cells by the integrin vitronectin receptor αVβ3
Khatib, A., Nip, J., Fallavollita, L., Lehmann, M., Jensen, G. S., & Brodt, P. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(200002)9999:9999 · Cited by 15
Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response
Huang, X., & Zuo, J. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt141 · Cited by 91
The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma
Yuen, J. S. P., Cockman, M. E., Sullivan, M., Protheroe, A. S., Turner, G. D. H., Roberts, I. S. D., Pugh, C. W., Werner, H., & Macaulay, V. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210474 · Cited by 89
Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2α/C-MYC axis under hypoxia
Zhai, W., Sun, Y., Jiang, M., Wang, M., Gasiewicz, T. A., Zheng, J., & Chang, C. (2016) · Oncogene · doi:10.1038/onc.2016.19 · Cited by 90
Genotype–phenotype correlations in von hippel–lindau disease
Neumann, H. P. H., & Bender, B. (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00336.x · Cited by 89
Bilateral non-familial renal cell carcinoma
Grimaldi, G., Reuter, V. E., & Russo, P. (1998) · Annals of Surgical Oncology · doi:10.1007/bf02303649 · Cited by 88
MDM2 SNP309 Polymorphism as Risk Factor for Susceptibility and Poor Prognosis in Renal Cell Carcinoma
Hirata, H., Hinoda, Y., Kikuno, N., Kawamoto, K., Suehiro, Y., Tanaka, Y., & Dahiya, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0609 · Cited by 88
FHIT mutations in human primary gastric cancer.
Gemma, A., Hagiwara, K., Ke, Y., Burke, L. M., Ma, K., Nagashima, M., Bennett, W. P., & Harris, C. C. (1997) · PubMed · Cited by 88
Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients
Greene, C. J., Attwood, K., Sharma, N. J., Gross, K. W., Smith, G. J., Xu, B., & Kauffman, E. C. (2017) · Oncotarget · doi:10.18632/oncotarget.22323 · Cited by 87
Renal cancer: molecular mechanisms and newer therapeutic options
Karumanchi, S. A., Merchan, J. R., & Sukhatme, V. P. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200201000-00006 · Cited by 87
Inactivation of von Hippel-Lindau Gene Induces Constitutive Phosphorylation of MET Protein in Clear Cell Renal Carcinoma
Nakaigawa, N., Yao, M., Baba, M., Kato, S., Kishida, T., Hattori, K., Nagashima, Y., & Kubota, Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0617 · Cited by 87
Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions
Gallou‐Kabani, C., Chauveau, D., Richard, S., Joly, D., Giraud, S., Olschwang, S., Martin, N., Saquet, C., Chrétien, Y., Méjean, A., et al. (2004) · Human Mutation · doi:10.1002/humu.20082 · Cited by 86
Von Hippel-Lindau disease and endocrine tumour susceptibility
Woodward, E. R., & Maher, E. R. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.00683 · Cited by 86
Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma
Okuda, H., Toyota, M., Ishida, W., Furihata, M., Tsuchiya, M., Kamada, M., Tokino, T., & Shuin, T. (2005) · Oncogene · doi:10.1038/sj.onc.1209200 · Cited by 86
Vascular endothelial growth factor‐targeted therapy in metastatic renal cell carcinoma
Rini, B. I. (2009) · Cancer · doi:10.1002/cncr.24227 · Cited by 85
Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications
Cresswell, G. D., Apps, J. R., Chagtai, T., Mifsud, B., Bentley, C. C., Maschietto, M. C., Popov, S. D., Weeks, M. E., Olsen, Ø. E., Sebire, N. J., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.05.029 · Cited by 85
Familial risk of cancer by site and histopathology
Hemminki, K., & Li, X. (2002) · International Journal of Cancer · doi:10.1002/ijc.10764 · Cited by 87
Structurally Modified Curcumin Analogs Inhibit STAT3 Phosphorylation and Promote Apoptosis of Human Renal Cell Carcinoma and Melanoma Cell Lines
Bill, M. A., Nicholas, C., Mace, T. A., Etter, J. P., Li, C., Schwartz, E. B., Fuchs, J. R., Young, G. S., Lin, L., Lin, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040724 · Cited by 84
Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma
Alimov, A. A., Kost‐Alimova, M., Liu, J., Li, C., Bergerheim, U. S. R., Imreh, S., Klein, G., & Zabarovsky, E. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203449 · Cited by 84
Loss of Heterozygosity and Copy Number Abnormality in Clear Cell Renal Cell Carcinoma Discovered by High-Density Affymetrix 10K Single Nucleotide Polymorphism Mapping Array
Toma, M. I., Großer, M., Herr, A., Aust, D. E., Meye, A., Hoefling, C., Fuessel, S., Wuttig, D., Wirth, M. P., & Baretton, G. B. (2008) · Neoplasia · doi:10.1593/neo.08160 · Cited by 83
Expression of the vitamin D receptor, 25-hydroxylases, 1α-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer
Jensen, M. B., Andersen, C. B., Nielsen, J. E., Bagi, P., Jørgensen, A., Juul, A., & Leffers, H. C. B. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.03.069 · Cited by 83
Suppression of T-cell responses by tumor metabolites
Singer, K., Gottfried, E., Kreutz, M. P., & Mackensen, A. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0967-1 · Cited by 84
Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system
Gläsker, S. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.5.644 · Cited by 82
Genome‐wide profiling of chromosomal alterations in renal cell carcinoma using high‐density single nucleotide polymorphism arrays
Chen, M., Ye, Y., Yang, H., Tamboli, P., Matin, S. F., Tannir, N. M., Wood, C. G., Gu, J. H., & Wu, X. (2009) · International Journal of Cancer · doi:10.1002/ijc.24642 · Cited by 86
Targeting the IGF1 axis in cancer proliferation
Bruchim, I., Attias-Geva, Z., & Werner, H. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903201702 · Cited by 82
Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies
Sakamoto, K. M. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00146-4 · Cited by 82
Successful Implementation of the Randomized Discontinuation Trial Design: An Application to the Study of the Putative Antiangiogenic Agent Carboxyaminoimidazole in Renal Cell Carcinoma—CALGB 69901
Stadler, W. M., Rosner, G. L., Small, E. J., Hollis, D. R., Rini, B. I., Zaentz, S. D., Mahoney, J. F., & Ratain, M. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.44.150 · Cited by 81
Pathology, genetics and cell biology of hemangioblastomas.
Wizigmann-Voos, S., & Plate, K. H. (1996) · PubMed · Cited by 81
Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis
Roh, S., Kasembeli, M. M., Bakthavatsalam, D., Chiu, W., & Tweardy, D. J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125975 · Cited by 81
The von Hippel-Lindau Tumor Suppressor Stabilizes Novel Plant Homeodomain Protein Jade-1
Zhou, M. I., Wang, H., Ross, J. J., Kuzmin, I., Xu, C., & Cohen, H. T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205040200 · Cited by 80
PHD2 in tumour angiogenesis
Chan, D. A., & Giaccia, A. J. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605682 · Cited by 80
The VHL tumor suppressor in development and disease: Functional studies in mice by conditional gene targeting
Haase, V. H. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2005.03.006 · Cited by 82
Metabolism of Kidney Cancer: From the Lab to Clinical Practice
Sudarshan, S., Karam, J. A., Brugarolas, J., Thompson, R. H., Uzzo, R. G., Rini, B. I., Margulis, V., Patard, J., Escudier, B. J., & Linehan, W. M. (2012) · European Urology · doi:10.1016/j.eururo.2012.09.054 · Cited by 79
Self-citation
The Evolving Role of Surgery for Advanced Renal Cell Carcinoma in the Era of Molecular Targeted Therapy
Rini, B. I., & Campbell, S. C. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.01.136 · Cited by 79
pVHL co‐ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear‐cell renal cell carcinoma
Struckmann, K., Mertz, K. D., Steu, S., Storz, M., Staller, P., Krek, W., Schraml, P., & Moch, H. (2008) · The Journal of Pathology · doi:10.1002/path.2310 · Cited by 80
Subclassification of renal cell neoplasms: an update for the practising pathologist
Renshaw, A. A. (2002) · Histopathology · doi:10.1046/j.1365-2559.2002.01420.x · Cited by 78
Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel–Lindau protein
Corn, P. G., McDonald, E. R., Herman, J. G., & El‐Deiry, W. S. (2003) · Nature Genetics · doi:10.1038/ng1254 · Cited by 78
Fusion of a novel gene, RCC17, to the TFE3 gene in t(X;17)(p11.2;q25.3)-bearing papillary renal cell carcinomas.
Heimann, P., Housni, H. E., Oğur, G., Weterman, M. A. J., Petty, E. M., & Vassart, G. (2001) · PubMed · Cited by 77
Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene
Hes, F. J., Zewald, R. A., Peeters, T., Sijmons, R. H., Links, T. P., Verheij, J., Matthijs, G., Legius, E., Mortier, G. R., van der Torren, K., et al. (2000) · Human Genetics · doi:10.1007/s004390000265 · Cited by 77
The VHL protein recruits a novel KRAB‐A domain protein to repress HIF‐1α transcriptional activity
Li, Z., Wang, D., Na, X., Schoen, S. R., Messing, E. M., & Wu, G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg173 · Cited by 77
Vascular endothelial growth factor overexpression is correlated with von Hippel‐Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma
Igarashi, H., Esumi, M., Ishida, H., & Okada, K. (2002) · Cancer · doi:10.1002/cncr.10635 · Cited by 77

Authors: Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D. R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, H., Pomer, S., Brooks, J. D., Isaacs, W. B., Lerman, M. I., Zbar, B., & Linehan, W. M.
Affiliations: National Cancer Institute (US)
Frederick National Laboratory for Cancer Research (US)
National Institutes of Health (US)
Cornell University (US)
University of Michigan (US)
Technical University of Munich (DE)
Heidelberg University (DE)
Johns Hopkins University (US)
ORCID: Gnarra, J.R.
Schmidt, L.
Wei, M.H.
Lubensky, I.
Bander, N.H.
Brauch, H.
Brooks, J.D.
Isaacs, W.B.
Lerman, M.I.
Linehan, W.M.
Venue: Nature Genetics
Publisher: Springer Science and Business Media LLC
Published: 1994-05
Volume: 7
Issue: 1
Pages: 85-90
ISSN: 1061-4036 (ISSN-L)
1546-1718
DOI: 10.1038/ng0594-85
OpenAlex: W2010160635
Cited by: 1,730
References: 29
Citations by year: 2026: 17 · 2025: 25 · 2024: 30 · 2023: 38 · 2022: 38 · 2021: 45 · 2020: 56 · 2019: 47 · 2018: 45 · 2017: 42 · 2016: 57 · 2015: 35 · 2014: 70 · 2013: 66 · 2012: 62
FWCI: 61.77
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Genetics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Health Sciences › Medicine › Oncology › Ear and Head Tumors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords: VHL gene, von Hippel-Lindau disease, renal carcinoma, clear cell renal cell carcinoma, loss of heterozygosity
MeSH terms: Base Sequence, Carcinoma, DNA Mutational Analysis, DNA, Neoplasm, von Hippel-Lindau Disease, Humans, Kidney Neoplasms, Molecular Sequence Data, Mutation, Organ Specificity, Polymorphism, Restriction Fragment Length, Genes, Tumor Suppressor, Neoplasms, Second Primary, Sequence Deletion, Adenocarcinoma, Clear Cell

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutations of the VHL tumour suppressor gene in renal carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks